Abstract
ObjectivesCompare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have